Skip to main content

Table 1 SARA baseline characteristics

From: Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis

  RA patients (n = 196) Blood donors (n = 101) p value
Characteristics
 Women, n (%) 156/196 (80) 54/101 (53) < 0.001
 Age, mean (range) 63.9 (25–87) 48.6 (20–74) < 0.001
 Disease duration years, mean (range) 12.2 (0–57)  
 Erosions, n (%) 109/193 (56)  
 Biologics, n (%) 72/196 (37)  
 Glucocorticoids, n (%) 52/196 (27)  
 Methotrexate, n (%) 148/196 (76)  
 Other csDMARD, n (%) 40/196 (20)  
Risk factors
 Ever smoker, n (%) 99/192 (52) 34/99 (34) 0.006
 Current smoker, n (%) 15/192 (8) 10/99 (10) 0.514
 Never smoker, n (%) 93/192 (48) 65/99 (66) 0.006
 Cigarette pack-years, mean (SD) 13.9 (13.8) 8.3 (11.3) 0.009
 Shared epitope carriage, n (%) 163/196 (83) 47/101 (47) < 0.001
 No allele, n (%) 34/196 (17) 54/101 (54) < 0.001
 One allele, n (%) 97/196 (50) 33/101 (33) 0.007
 Two alleles, n (%) 65/196 (33) 14/101 (14) < 0.001
Antibodies
 RF-positive, n (%) 145/195 (74)  
 IgG ACPA
  Positive, n (%) 157/196 (80) 0/101 (0) < 0.001
  Level, median U/mL (SD) 444.1 (923.8) 0.1 (0.0) < 0.001
 IgA ACPA
  Positive, n (%) 88/196 (45) 0/101 (0) < 0.001
  Level, median AU/mL (SD) 1.3 (151.9) 1.3 (0.0) < 0.001
Level total IgA in serum, median g/L (SD) 2.5 (1.4) 2.0 (0.7) < 0.001
Level total IgA in saliva, median μg/mL (SD) 61.5 (85.8) 35.7 (24.7) < 0.001
  1. Abbreviations: csDMARDs conventional disease-modifying anti-rheumatic drugs, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptides